High tumor expression of BARD1 (HR, 1.655; 95% CI, 1.100–2.489; P = 0.016), size of tumor >5 cm (HR, 2.160; 95% CI, 1.308–3.568); P = 0.003), TNM stage III-IV (HR, 1.980; 95% CI, 1.198–3.272; P = 0.008), and increased serum AST levels (HR, 1.637; 95% CI, 1.052–2.546; P = 0.029), recurrence (HR, 2.736; 95% CI, 1.756–4.264; P < 0.001) were significant independent prognostic factors for shorter OS in HCC patients (Table 3). The gene discussed is BARD1; the disease is neoplasm.